🇺🇸 FDA
Pipeline program

Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe

219871

Approved small_molecule active

Quick answer

Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled syringe, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled pen, Nucala 100 mg solution for injection in pre-filled syringe for severe asthma is a Approved program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline Biologicals S.A.
Indication
severe asthma
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials